Φορτώνει......
Relapsed Myasthenia Gravis after Nivolumab Treatment
Nivolumab is a newly introduced promising therapy for treating lung cancer that restores the anti-tumor immunity by disrupting programmed cell death-1-mediated immuno-suppressive signaling. Although “new-onset” autoimmune diseases are well-known immune-related adverse events, whether or not nivoluma...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Intern Med |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
The Japanese Society of Internal Medicine
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6064691/ https://ncbi.nlm.nih.gov/pubmed/29434145 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.9153-17 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|